Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy chinese volunteers

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1446-1454

  Wu, Xiao Jie ^a,b   Zhang, Jing ^a,b   Guo, Bei Ning ^a,b   Zhang, Ying Yuan ^a,b   Yu, Ji Cheng ^a,b   Cao, Guo Ying ^a,b   Chen, Yuan Cheng ^a,b   Zhu, De Mei ^a   Ye, Xin Yu ^a,b   Wu, Ju Fang ^a,b   Shi, Yao Guo ^a,b   Chang, Li Wen ^c   Chang, Yu Ting ^c   Tsai, Cheng Yuan ^c  

^a FUDAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c TaiGen Biotechnology Co Ltd   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; NEMONOXACIN; PLACEBO; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHINESE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; INFUSION RATE; INJECTION SITE REACTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; MORAXELLA CATARRHALIS; MULTIPLE DRUG DOSE; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT RESPONSE; URINARY EXCRETION; ADOLESCENT; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MIDDLE AGED;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; QUINOLONES;

EID: 84923242899     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04039-14     Document Type: Article

References (22)

1. Roychoudhury S, Twinem TL, Makin KM, McIntosh EJ, Ledoussal B, Catrenich CE. 2001. Activity of nonfluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae. J Antimicrob Chemother 48:29-36. http://dx.doi.org/10.1093/jac/48.1.29.
2. Roychoudhury S, Ledoussal B. 2002. Nonfluorinated quinolones (NFQs): new antibacterials with unique properties against quinoloneresistant Gram-positive pathogens. Curr Drug Targets Infect Disord 2:51-65. http://dx.doi.org/10.2174/1568005024605891.
3. Chen SJ, Lin L, Chang LW. 2007. Analysis of antibacterial response of nemonoxacin (TG-873870) against major pathogens from respiratory tract and skin infections, abstr 441. Abstr 45th Infect Dis Soc Am Meet. Infectious Diseases Society of America, Washington, DC.
4. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. 2010. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother 54:1338-1342. http://dx.doi.org/10.1128/AAC.01197-09.
5. Pankuch GA, Kosowska-Shick K, McGhee P, King CHR, Appelbaum PC. 2008. Comparative antistaphylococcal activity of nemonoxacin, a novel broad-spectrum quinolone, abstr C1-189. Abstr 48th Intersci Conf Antimicrob Agents Chemother (ICAAC)-Infect Dis Soc Am (IDSA) 46th Annu Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
6. Zhanel GG, Laing N, DeCorby M, Nichol K, King CHR, Adam H, Hoban DJ. 2008. Activity of nemonoxacin, an investigational C8-methoxy nonfluorinated quinolone against Gram-positive cocci obtained from Canadian hospitals: CANWARD 2007, abstr F1-2057. Abstr 48th Intersci Conf Antimicrob Agents Chemother (ICAAC)-Infect Dis SocAm (IDSA) 46th Annu Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
7. King CHR, Lin L, Leunk R. 2008. In vitro resistance development to nemonoxacin for Streptococcus pneumoniae, abstr C1-1971. Abstr 48th Intersci Conf Antimicrob Agents Chemother (ICAAC)-Infect Dis SocAm (IDSA) 46th Annu Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
8. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG. 2009. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 53:4915-4920. http://dx.doi.org/10.1128/AAC.00078-09.
9. Qin X, Huang H. 2014. Review of nemonoxacin with special focus on clinical development. Drug Des Devel Ther 8:765-774. http://dx.doi.org/10.2147/DDDT.S63581.
10. Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR. 2009. In vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother 64:1226-1229. http://dx.doi.org/10.1093/jac/dkp370.
11. Lin L, Chang LW, Tsai CY, Hsu CH, Chung DT, Aronstein WS, Ajayi F, Kuzmak B, Lyon RA. 2010. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 54:405-410. http://dx.doi.org/10.1128/AAC.00682-09.
12. Chung DT, Tsai CY, Chen SJ, Chang LW, King CH, Hsu CH, Chiu KM, Tan HC, Chang YT, Hsu MC. 2010. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob Agents Chemother 54:411-417. http://dx.doi.org/10.1128/AAC.00683-09.
13. Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G, Zhang J. 2012. Safety and clinical pharmacokinetics of nemonoxacin, a novel nonfluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig 32:475-486. http://dx.doi.org/10.2165/11632780-000000000-00000.
14. Cao GY, Zhang J, Zhang YY, Guo BN, Yu JC, Wu XJ, Chen YC, Wu JF, Shi YG. 2014. Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy Chinese volunteers. Antimicrob Agents Chemother 58:6116-6121. http://dx.doi.org/10.1128/AAC.02972-14.
15. Guo B, Zhang J, Yu J, Wu X, Shi Y, Tsai CY. 2012. A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunteers. Biomed Chromatogr 26:1333-1340. http://dx.doi.org/10.1002/bmc.2699.
16. Liang W, Chen YC, Cao YR, Liu XF, Huang J, Hu JL, Zhao M, Guo QL, Zhang SJ, Wu XJ, Zhu DM, Zhang YY, Zhang J. 2013. Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 57:2942-2947. http://dx.doi.org/10.1128/AAC.01098-12.
17. Cao G, Zhang J, Wu X, Yu J, Chen Y, Ye X, Zhu D, Zhang Y, Guo B, Shi Y. 2013. Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization. J Clin Pharm Ther 38:394-400. http://dx.doi.org/10.1111/jcpt.12074.
18. Kotapati S, Kuti JL, Nicolau DP. 2005. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program. Surg Infect (Larchmt) 6:297-304. http://dx.doi.org/10.1089/sur.2005.6.297.
19. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. 2003. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 43:1116-1123. http://dx.doi.org/10.1177/0091270003257225.
20. Burgess DS, Hall RG, 2nd. 2007. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data. Clin Ther 29:1421-1427. http://dx.doi.org/10.1016/j.clinthera.2007.07.024.
21. Frei CR, Burgess DS. 2008. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against Gram-negative pulmonary isolates from patients managed in intensive care units in 2002. Clin Ther 30:2335-2341. http://dx.doi.org/10.1016/j.clinthera.2008.12.009.
22. Zhang J, Yu JC, Shi YG, Zhou L, Ye XY, Zhu DM, Zhang YY. 2005. Study of pharmacokinetics/pharmacodynamics of levofloxacin. Zhonghua Yi Xue Za Zhi 85:1926-1932. (In Chinese.)